![](/images/graphics-bg.png)
In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study
Joint Authors
Huang, David B.
Hawser, Stephen
Gemmell, Curtis G.
Sahm, Daniel F.
Source
Canadian Journal of Infectious Diseases and Medical Microbiology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-12-17
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria.
Daptomycin, linezolid, and vancomycin are commonly used antibiotics for these indications.
With increased selective pressure to these antibiotics, outbreaks of bacterial resistance to these antibiotics have been reported.
This in vitro pilot study evaluated the activity of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA) isolates, which were also not susceptible to daptomycin, linezolid, or vancomycin.
Iclaprim had an MIC ≤ 1 µg/ml to the majority of MRSA isolates that were nonsusceptible to daptomycin (5 of 7 (71.4%)), linezolid (26 of 26 (100%)), or vancomycin (19 of 28 (66.7%)).
In the analysis of time-kill curves, iclaprim demonstrated ≥ 3 log10 reduction in CFU/mL at 4–8 hours for tested strains and isolates nonsusceptible to daptomycin, linezolid, or vancomycin.
Together, these data support the use of iclaprim in serious infections caused by MRSA nonsusceptible to daptomycin, linezolid, or vancomycin.
American Psychological Association (APA)
Huang, David B.& Hawser, Stephen& Gemmell, Curtis G.& Sahm, Daniel F.. 2017. In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1141560
Modern Language Association (MLA)
Huang, David B.…[et al.]. In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2017 (2017), pp.1-6.
https://search.emarefa.net/detail/BIM-1141560
American Medical Association (AMA)
Huang, David B.& Hawser, Stephen& Gemmell, Curtis G.& Sahm, Daniel F.. In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study. Canadian Journal of Infectious Diseases and Medical Microbiology. 2017. Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1141560
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141560